Quick Answer
Amylyx Pharmaceuticals, Inc. reported Stockholders Equity of $305.26 million for the year ending 2025.
- Amylyx Pharmaceuticals, Inc. showed an increase of +85.3% in Stockholders Equity from 2024 to 2025.
- This data is from Amylyx Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$80.63 million | Q2 2021: -$101.89 million | Q3 2021: -$124.07 million | Q1 2022: $240.95 million | Q2 2022: $192.79 million | Q3 2022: $144.03 million | Q1 2023: $352.65 million | Q2 2023: $386.37 million | Q3 2023: $418.40 million | Q1 2024: $324.44 million | Q2 2024: $261.31 million | Q3 2024: $196.20 million | Q1 2025: $201.42 million | Q2 2025: $167.88 million | Q3 2025: $332.00 million.
- Over the full 6 years of available data (2020 to 2025), Amylyx Pharmaceuticals, Inc.'s Stockholders Equity has grown by 557.5%.
- Historical annual values: Fiscal year 2025: $305.26 million | Fiscal year 2024: $164.77 million | Fiscal year 2023: $433.43 million | Fiscal year 2022: $340.61 million | Fiscal year 2021: -$151.17 million | Fiscal year 2020: -$66.73 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: